Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
Identifieur interne : 000808 ( Istex/Corpus ); précédent : 000807; suivant : 000809Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
Auteurs : Jean-Louis Montastruc ; Karine Desboeuf ; Maryse Lapeyre-Mestre ; Jean-Michel Senard ; Olivier Rascol ; Christine Brefel-CourbonSource :
- Movement Disorders [ 0885-3185 ] ; 2001-05.
English descriptors
- KwdEn :
Abstract
The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1093
Links to Exploration step
ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1093</idno><idno type="url">https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000808</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000808</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-05">2001-05</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="511">511</biblScope><biblScope unit="page" to="514">514</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><idno type="DOI">10.1002/mds.1093</idno><idno type="ArticleID">MDS1093</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>bromocriptine</term><term>levodopa</term><term>mortality</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jean‐Louis Montastruc MD, PhD</name><affiliations><json:string>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</json:string><json:string>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</json:string></affiliations></json:item><json:item><name>Karine Desboeuf MD</name><affiliations><json:string>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</json:string></affiliations></json:item><json:item><name>Maryse Lapeyre‐Mestre MD</name><affiliations><json:string>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</json:string></affiliations></json:item><json:item><name>Jean‐Michel Senard MD, PhD</name><affiliations><json:string>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</json:string></affiliations></json:item><json:item><name>Christine Brefel‐Courbon MD</name><affiliations><json:string>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>bromocriptine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mortality</value></json:item></subject><articleId><json:string>MDS1093</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>shortCommunication</json:string></originalGenre><abstract>The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</abstract><qualityIndicators><score>4.711</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1368</abstractCharCount><pdfWordCount>2119</pdfWordCount><pdfCharCount>13280</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>216</abstractWordCount></qualityIndicators><title>Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><refBibs><json:item><author><json:item><name>WJ Weiner</name></json:item></author><host><volume>5</volume><pages><last>724</last><first>716</first></pages><author></author><title>Mov Disord</title></host><title>The initial treatment of Parkinson's disease should begin with levodopa</title></json:item><json:item><author><json:item><name>JL Montastruc</name></json:item><json:item><name>O Rascol</name></json:item><json:item><name>JM Senard</name></json:item></author><host><volume>5</volume><pages><last>730</last><first>725</first></pages><author></author><title>Mov Disord</title></host><title>Treatment of Parkinson's disease should begin with a dopamine agonist</title></json:item><json:item><author><json:item><name>JL Montastruc</name></json:item><json:item><name>O Rascol</name></json:item><json:item><name>JM Senard</name></json:item><json:item><name>A Rascol</name></json:item></author><host><volume>57</volume><pages><last>1038</last><first>1034</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow‐up</title></json:item><json:item><author><json:item><name>UK Rinne</name></json:item><json:item><name>F Bracco</name></json:item><json:item><name>C Chouza</name></json:item><json:item><name>E Dupont</name></json:item><json:item><name>O Gershanik</name></json:item><json:item><name>JF Marti Masso</name></json:item><json:item><name>JL Montastruc</name></json:item><json:item><name>CD Marsden</name></json:item><json:item><name> </name></json:item></author><host><volume>55</volume><pages><last>30</last><first>23</first></pages><issue>Suppl 1</issue><author></author><title>Drugs</title></host><title>Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double‐blind levodopa controlled trial</title></json:item><json:item><author><json:item><name>O Rascal</name></json:item><json:item><name>DJ Brooks</name></json:item><json:item><name>AD Korczyn</name></json:item><json:item><name>PP De Deyn</name></json:item><json:item><name>CE Clarke</name></json:item><json:item><name>AE Lang</name></json:item></author><host><volume>342</volume><pages><last>1491</last><first>1484</first></pages><author></author><title>N Eng J Med</title></host><title>A five‐year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa</title></json:item><json:item><author><json:item><name>H Przuntek</name></json:item><json:item><name>D Welzel</name></json:item><json:item><name>E Blümmer</name></json:item></author><host><volume>43</volume><pages><last>363</last><first>357</first></pages><author></author><title>Eur J Clin Pharmacol</title></host><title>Bromocriptine lessens the incidence of mortality in L‐Dopa treated parkinsonian patients: Prado Study discontinued</title></json:item><json:item><author><json:item><name>MA Hely</name></json:item><json:item><name>JGL Morris</name></json:item><json:item><name>R Traficante</name></json:item></author><host><volume>67</volume><pages><last>307</last><first>300</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>The Sydney multicentre study of Parkinson's disease:progression and mortality at 10 years</title></json:item><json:item><host><author></author><title>Statistical methods in cancer research: the design and analysis of cohort studies</title></host></json:item><json:item><author><json:item><name>WR Gibbs</name></json:item><json:item><name>AJ Lees</name></json:item></author><host><volume>51</volume><pages><last>752</last><first>745</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>The relevance of the Lewy body to the pathogenis of idiopathic Parkinson's disease</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>P Jenner</name></json:item><json:item><name>D Brooks</name></json:item></author><host><volume>44</volume><pages><last>174</last><first>167</first></pages><issue>Suppl 1</issue><author></author><title>Ann Neurol</title></host><title>Dopamine agonists and neuroprotection in Parkinson's disease</title></json:item><json:item><author><json:item><name>JL Montastruc</name></json:item><json:item><name>O Rascol</name></json:item><json:item><name>JM Senard</name></json:item></author><host><volume>347</volume><pages><first>196</first></pages><author></author><title>Lancet</title></host><title>Neuroprotection in Parkinson's disease</title></json:item><json:item><author><json:item><name>DA Bennet</name></json:item><json:item><name>LA Beckett</name></json:item><json:item><name>AM Murray</name></json:item><json:item><name>KM Shannon</name></json:item><json:item><name>CG Goetz</name></json:item><json:item><name>DM Pilgrim</name></json:item><json:item><name>DA Evans</name></json:item></author><host><volume>334</volume><pages><last>76</last><first>71</first></pages><author></author><title>N Eng J Med</title></host><title>Prevalence of parkinsonian signs and associated mortality in a community population of older people</title></json:item><json:item><author><json:item><name>ED Louis</name></json:item><json:item><name>K Marsden</name></json:item><json:item><name>L Cote</name></json:item><json:item><name>M Tang</name></json:item><json:item><name>R Mayeux</name></json:item></author><host><volume>54</volume><pages><last>264</last><first>260</first></pages><author></author><title>Arch Neurol</title></host><title>Mortality from Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>43</volume><pages><last>325</last><first>318</first></pages><author></author><title>Ann Neurol</title></host><title>DATATOP: Mortality in a multicenter trial in early Parkinson's disease</title></json:item><json:item><author><json:item><name>A Guillard</name></json:item><json:item><name>C Chastang</name></json:item><json:item><name>G Fenelon</name></json:item></author><host><volume>142</volume><pages><last>214</last><first>207</first></pages><author></author><title>Rev Neurol (Paris)</title></host><title>Long‐term study of 416 cases of Parkinson's disease. Pronostic factors and therapeutic implications</title></json:item></refBibs><genre><json:string>brief-communication</json:string></genre><host><volume>16</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>514</last><first>511</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1002/mds.1093</json:string></doi><id>DB129378E12554A8F9378511E8F16E3C6FB4CCFD</id><score>0.13397987</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>Copyright © 2001 Movement Disorder Society</p></availability><date>2001</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Jean‐Louis</forename><surname>Montastruc</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><affiliation>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Karine</forename><surname>Desboeuf</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Maryse</forename><surname>Lapeyre‐Mestre</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Jean‐Michel</forename><surname>Senard</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Christine</forename><surname>Brefel‐Courbon</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-05"></date><biblScope unit="volume">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="511">511</biblScope><biblScope unit="page" to="514">514</biblScope></imprint></monogr><idno type="istex">DB129378E12554A8F9378511E8F16E3C6FB4CCFD</idno><idno type="DOI">10.1002/mds.1093</idno><idno type="ArticleID">MDS1093</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>bromocriptine</term></item><item><term>levodopa</term></item><item><term>mortality</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-05-15">Received</change><change when="2000-09-21">Registration</change><change when="2001-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/DB129378E12554A8F9378511E8F16E3C6FB4CCFD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v16:3</doi><numberingGroup><numbering type="journalVolume" number="16">16</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2001-05">May 2001</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="16" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.1093</doi><idGroup><id type="unit" value="MDS1093"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2001 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2000-05-15"></event><event type="manuscriptRevised" date="2000-09-16"></event><event type="manuscriptAccepted" date="2000-09-21"></event><event type="publishedOnlineEarlyUnpaginated" date="2001-05-09"></event><event type="firstOnline" date="2001-05-09"></event><event type="publishedOnlineFinalForm" date="2001-05-30"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">511</numbering><numbering type="pageLast">514</numbering></numberingGroup><correspondenceTo>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1093.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2033"></count></countGroup><titleGroup><title type="main" xml:lang="en">Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title><title type="short" xml:lang="en">Bromocriptine and Mortality</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jean‐Louis</givenNames><familyName>Montastruc</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>montastruc@cict.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Karine</givenNames><familyName>Desboeuf</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Maryse</givenNames><familyName>Lapeyre‐Mestre</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jean‐Michel</givenNames><familyName>Senard</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christine</givenNames><familyName>Brefel‐Courbon</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">bromocriptine</keyword><keyword xml:id="kwd3">levodopa</keyword><keyword xml:id="kwd4">mortality</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Bromocriptine and Mortality</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Jean‐Louis</namePart><namePart type="family">Montastruc</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><affiliation>Service de Pharmacologie Clinique, Faculté de Médecine, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karine</namePart><namePart type="family">Desboeuf</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maryse</namePart><namePart type="family">Lapeyre‐Mestre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean‐Michel</namePart><namePart type="family">Senard</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel‐Courbon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Faculté de Médecine and Hôpitaux de Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="shortCommunication"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2001-05</dateIssued><dateCaptured encoding="w3cdtf">2000-05-15</dateCaptured><dateValid encoding="w3cdtf">2000-09-21</dateValid><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">15</extent><extent unit="words">2033</extent></physicalDescription><abstract lang="en">The present paper compares, in terms of mortality, two treatment regimens for Parkinson's disease (PD), i.e., bromocriptine later combined with levodopa versus levodopa only. Between 1982 and 1989, 60 PD patients (29 treated with levodopa alone [group D] and 31 receiving first bromocriptine followed by an association of bromocriptine + levodopa [group B/D]) were recruited. Data were updated in January 2000. Survival functions were estimated using Kaplan Meier product‐limit method and comparison between the two groups with the log‐rank test. Mortality was also compared with that of the general French population using standardized mortality ratios (SMRs). The mean duration of follow‐up was 10.3 ± 3.0 years. Seventeen patients died during the follow‐up: nine in the group B/D and eight in the group D. The probability of survival at 10 years was 79.0% [95% confidence interval [CI]: 71.4–86.6] in group B/D and 72.9% [95% CI: 63.3–82.6] in group D. In comparison with the general French population, SMRs were not statistically different from 1, in the whole sample of PD patients (1.21, 95 % CI [0.71–1.95]), in group D (0.98 [0.42–1.93]), or in group B/D (1.53 [0.70–2.92]). In this population, we were unable to find any favourable effect of an early use of bromocriptine on mortality in PD in comparison with levodopa alone. © 2001 Movement Disorder Society.</abstract><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>bromocriptine</topic><topic>levodopa</topic><topic>mortality</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>511</start><end>514</end><total>4</total></extent></part></relatedItem><identifier type="istex">DB129378E12554A8F9378511E8F16E3C6FB4CCFD</identifier><identifier type="DOI">10.1002/mds.1093</identifier><identifier type="ArticleID">MDS1093</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2001 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000808 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000808 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DB129378E12554A8F9378511E8F16E3C6FB4CCFD
|texte= Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |